Radius announces results from the wearable trial evaluating abaloparatide transdermal system in postmenopausal women with osteoporosis

Boston, dec. 08, 2021 (globe newswire) -- radius health, inc. (“radius” or the “company”) (nasdaq: rdus), today announced phase 3 topline results from the wearable study evaluating the non-inferiority (ni) of abaloparatide transdermal system (abalo-tds) compared to abaloparatide subcutaneous injection (tymlos) in postmenopausal women with osteoporosis.
RDUS Ratings Summary
RDUS Quant Ranking